Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 6,700 shares at $7.66 ($51K) on 2023-02-17, disclosed to the SEC on 2023-02-23.
Open-market sale of $51k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |